The company's three-quarter report shows that from January to September 2009, the company achieved operating income of 103 million yuan, an increase of 19.24% over the previous year; operating profit loss of 5.44 million yuan, compared with 2.12 million yuan in the same period last year; loss of 5.75 million yuan in net profit attributable to the parent company, compared with 1.9 million yuan in the same period last year; and earnings per diluted share - 0.05 yuan. The promotion of commercial products has increased, and sales expenses have risen. The company continued to expand sales channels and increase the promotion of commercial products from January to September, achieving revenue of 103 million yuan, an increase of 19.24% over the previous year; at the same time, due to increased sales efforts, sales expenses increased. Sales expenses during the reporting period were 58.08 million yuan, an increase of 26.22% year on year, and the sales expense ratio was 56.23%, up 3.11 percentage points year on year. Management costs are rising. Management expenses increased due to increased labor costs and amortization of intangible assets. Management expenses during the reporting period were 16.32 million yuan, an increase of 20.07% over the previous year, and the management expenses ratio was 15.80%, an increase of 2.89 percentage points over the previous year. There was a loss in net profit. The main reason for the loss was rising costs due to falling unit prices for pharmaceuticals, increased investment in market development expenses for new products, increased human resources costs, and rising prices of raw materials for traditional Chinese medicines, etc., which ate up operating profits. It is expected that the restructuring will be completed within 2009, and it will be transformed into a city operator. On July 8, 2009, the company issued a major asset sale and non-public offering plan. The transaction is carried out in two steps: (1) Overall asset sale. Zhonghui Pharmaceutical plans to sell all of its assets and liabilities to Yihe Group, the controlling shareholder of its largest shareholder, MetLife Pharmaceuticals, with an estimated valuation of 147 million yuan. Yihe Group will pay a one-time consideration in cash; (2) purchase assets from specific target non-public shares. Zhonghui Pharmaceutical plans to purchase 100% of its shares in Tieling Caijing from Tieling Finance Company, Jingrun Blue Chip, Sanzhu Jiahe, Mr. Luo De'an, and Mr. Fu Ju. Tieling Caijing is the only integrated urban operator in Tieling New Town, Liaoning. It is responsible for the construction and operation of urban infrastructure for first-level land development in the city's Xincheng District. After the transaction is completed, Zhonghui Pharmaceutical will become a comprehensive urban operator, and its main business will change to first-level land development and municipal infrastructure supporting construction and operation. Through this transaction, while selling all of the original assets and liabilities and obtaining cash, shares in high-quality companies were obtained, and the company's profitability will be significantly improved. If all goes well, Zhonghui Pharmaceutical is expected to complete the restructuring within this year, and the company will officially “transform” into a city operator at that time. Profit forecast: Since the company is about to be restructured and the main business will be changed at that time, we will not give profit forecasts and investment ratings for the company, and remind investors to pay attention to related trading opportunities and risks.